Endokrine Interventionen bei BRCA1/2-Mutationsträgerinnen

Deborah R. Huber; Stephan Seitz; Olaf Ortmann

doi:10.1055/a-1372-7776

Frauenheilkunde up2date, Table of Contents

Frauenheilkunde up2date 2021; 15(05): 399-410
DOI: 10.1055/a-1372-7776

Gynäkologische Onkologie

Endokrine Interventionen bei BRCA1/2-Mutationsträgerinnen

Deborah R. Huber

,

Stephan Seitz

,

Olaf Ortmann

Abstract

All articles of this category

BRCA1/2-Mutationsträgerinnen haben ein erhöhtes Risiko für Mamma- und Ovarialkarzinom. Das mediane Erkrankungsalter beträgt 44 bzw. 54 Jahre für BRCA1- und 48 bzw. 59 Jahre für BRCA2-Mutationsträgerinnen [1]. In der klinischen Praxis stellt sich bei diesen Patientinnen häufig auch die Frage nach der onkologischen Sicherheit endokriner Interventionen. Dieser Beitrag stellt die aktuelle Datenlage dar.

Schlüsselwörter

BRCA - HRT - Kontrazeption - Kinderwunschbehandlung - Krebsrisiko

Full Text

References

Literatur
1 Kuchenbaecker KB, Hopper JL, Barnes DR. et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA 2017; 317 (23) 2402-2416
2 Mørch LS, Hannaford PC, Lidegaard Ø. Contemporary Hormonal Contraception and the Risk of Breast Cancer. N Engl J Med 2018; 378 (13) 1265-1266
3 Beral V, Doll R, Hermon C. et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008; 371(9609): 303-314
4 Moorman PG, Havrilesky LJ, Gierisch JM. et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol 2013; 31 (33) 4188-4198
5 Cibula D, Zikan M, Dusek L. et al. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Rev Anticancer Ther 2011; 11 (08) 1197-1207
6 Perri T, Lifshitz D, Sadetzki S. et al. Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers. Fertil Steril 2015; 103 (05) 1305-1312
7 Kotsopoulos J, Lubinski J, Moller P. et al. Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. Breast Cancer Res Treat 2014; 143 (03) 579-586
8 Rieder V, Salama M, Glöckner L. et al. Effect of lifestyle and reproductive factors on the onset of breast cancer in female BRCA 1 and 2 mutation carriers. Mol Genet Genomic Med 2016; 4 (02) 172-177
9 Schrijver LH, Olsson H, Phillips K-A. et al. Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. JNCI Cancer Spectr 2018; 2 (02) pky023
10 Cibula D, Gompel A, Mueck AO. et al. Hormonal contraception and risk of cancer. Hum Reprod Update 2010; 16 (06) 631-650
11 Rizzuto I, Behrens RF, Smith LA. Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility. Cochrane Database Syst Rev 2019; (06) CD008215
12 Oktay K, Kim JY, Barad D. et al. Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J Clin Oncol 2010; 28 (02) 240-244
13 Gronwald J, Glass K, Rosen B. et al. Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Fertil Steril 2016; 105 (03) 781-785
14 Kotsopoulos J, Librach CL, Lubinski J. et al. Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study. Cancer Causes Control 2008; 19 (10) 1111-1119
15 Kim J, Turan V, Oktay K. Long-Term Safety of Letrozole and Gonadotropin Stimulation for Fertility Preservation in Women With Breast Cancer. J Clin Endocrinol Metab 2016; 101 (04) 1364-1371
16 Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) e.V.. et al. S3-Leitlinie Peri- und Postmenopause – Diagnostik und Interventionen: AWMF-Registernummer: 015 – 062; 2020.
17 Domchek SM, Friebel TM, Singer CF. et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010; 304 (09) 967-975
18 Parker WH, Broder MS, Chang E. et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nursesʼ health study. Obstet Gynecol 2009; 113 (05) 1027-1037
19 Manson JE, Chlebowski RT, Stefanick ML. et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Womenʼs Health Initiative randomized trials. JAMA 2013; 310 (13) 1353-1368
20 Kotsopoulos J, Lubinski J, Neuhausen SL. et al. Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Gynecol Oncol 2006; 100 (01) 83-88
21 Rebbeck TR, Levin AM, Eisen A. et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999; 91 (17) 1475-1479
22 Kotsopoulos J, Huzarski T, Gronwald J. et al. Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study. Breast Cancer Res Treat 2016; 155 (02) 365-373
23 Marchetti C, Felice F de Boccia S. et al. Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis. Crit Rev Oncol Hematol 2018; 132: 111-115
24 Michaelson-Cohen R, Gabizon-Peretz S, Armon S. et al. Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy. Eur J Cancer 2021; 148: 95-102
25 Segev Y, Iqbal J, Lubinski J. et al. The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. Gynecol Oncol 2013; 130 (01) 127131
26 Shu CA, Pike MC, Jotwani AR. et al. Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. JAMA Oncol 2016; 2 (11) 1434-1440
27 Segev Y, Rosen B, Lubinski J. et al. Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study. Fam Cancer 2015; 14 (03) 383-391
28 Marchetti C, Felice F de Palaia I. et al. Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers. BMC Womens Health 2014; 14: 150
29 Mavaddat N, Antoniou AC, Mooij TM. et al. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. Breast Cancer Res 2020; 22 (01) 8